Pharmacokinetics & Metabolism

Absorption from food

Apigenin is consumed from food mainly as glycosides. Before absorption, gut enzymes — including epithelial β-glucosidases in the small intestine and microbial enzymes in the colon — must cleave the sugar and release free aglycone.

That conversion varies between individuals and depends partly on gut microbiome composition.

Free apigenin is lipophilic and a weak acid. It is better absorbed in low-pH environments, especially in the stomach and upper small intestine. It can be absorbed across the full gastrointestinal tract, but appears to absorb most efficiently at the upper end.

Bioavailability

Calculated relative oral bioavailability is about 30%, which is low by small-molecule drug standards.

After oral dosing, peak plasma concentration is usually reached within 0.5 to 2.5 hours, with significant inter-study and inter-individual variability. Average elimination half-life is about 2.52 hours, with a reported range of roughly 1.8 to 4.2 hours.

Systemic exposure is therefore relatively short-lived. With regular dosing, steady state would be expected within roughly 12 hours.

Metabolism

After absorption, apigenin undergoes phase II metabolism in the gut and liver, producing mainly glucuronide and sulphate conjugates.

These conjugates can undergo enterohepatic recirculation. That prolongs gastrointestinal presence, but reduces net systemic levels of free apigenin.

Tissue distribution

Apigenin’s logP value of about 2.84 means it is lipophilic enough to cross cell membranes readily, including the blood-brain barrier.

Human tissue-distribution data remain limited. Animal data suggest reasonable tissue uptake.

Transporters

Apigenin inhibits ABC drug-efflux transporters, including P-glycoprotein and BCRP, in intestinal epithelial models.

That may raise intracellular concentrations of co-administered drugs and adds another interaction layer beyond CYP enzymes. For practical implications, see Safety & Interactions and Dosing & Timing.

Microbiome dependence

Gut microbiota can further degrade apigenin and its metabolites into smaller phenolic compounds.

Microbiome diversity and gut health influence the completeness of glycoside conversion to active aglycone. That contributes to the high inter-individual variability seen with food-derived apigenin. Liposomal formulations reduce reliance on that step.

Main translational bottleneck

The central problem is poor and variable oral bioavailability combined with short half-life and extensive first-pass metabolism.

Achieving tissue concentrations that match preclinical anticancer activity is not reliably possible through normal dietary intake or conventional standard supplementation alone. Estimates suggest that the roughly 1–5 µM in vitro activity range would require intake far above usual food exposure.

That gap is why enhanced-delivery systems have become such a central part of the apigenin discussion. For formulation context, see Liposomal Encapsulation of Anti-cancer Compounds.

References

• Chmielewska M, et al. Does Oral Apigenin Have Real Potential for a Therapeutic Effect in Cancer?

• Liang Y, et al. A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota

• Xu M, et al. Absorption, distribution, metabolism and excretion of apigenin

• Hou M, et al. Recent advancement in bioeffect, metabolism, stability, and delivery systems of apigenin